Zhejiang Provincial Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Su, Heng
ESPTTN, NCT06423235: Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules

Not yet recruiting
4
426
RoW
regular dose of JiRui® Prunella oral liquid, 2x regular dose of JiRui® Prunella oral liquid, regular dose of placebo, 2x regular dose of placebo
Xintian Pharmaceutical
Thyroid Nodule
07/25
07/28
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
08/25
08/25
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NCT05593081: Multicenter Study of Fulminant Type 1 Diabetes in China

Recruiting
N/A
240
RoW
HLA
Second Xiangya Hospital of Central South University
Diabetes Mellitus, Type 1
12/27
12/27
NCT05498974: China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes

Recruiting
N/A
20000
RoW
Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Second Xiangya Hospital of Central South University
Type1diabetes, Diabetes
12/35
12/35

Download Options